Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 2, 1998, Pages 192-203

  Ragueneau, Isabelle ^b   Laveille, Christian ^b   Jochemsen, Roeline ^b   Resplandy, Guillemette ^b   Funck Brentano, Christian ^a   Jaillon, Patrice ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; DRUG METABOLITE; IVABRADINE; S 18982; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRADYCARDIA; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HEART MUSCLE ISCHEMIA; HEART RATE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SINUS NODE; VISUAL IMPAIRMENT;

ADULT; BENZAZEPINES; CARDIOTONIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXERCISE TEST; HEART RATE; HUMANS; MALE; REFERENCE VALUES;

EID: 0031685461     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90153-9     Document Type: Article

References (18)

1. Frishman WH. Beta-adrenergic blockade for the treatment of angina pectoris. In: Weiner DA, Frishman WH, editors. Therapy of angina pectoris: a comprehensive guide for the clinician. New York: Marcel Dekker; 1986. p. 83-144.
2. Frishman WH. Multifactorial actions of β-adrenergic blocking drugs in ischemic heart disease. Circulation 1983;67(Suppl I):II-8.
3. Frishman WH, Sonnenblick EH. Calcium-channel blockers. In: Schlant RC, Alexander R, editors. The heart. 8th ed. New York: McGraw Hill; 1994. p. 1291-308.
4. Opie LH. Pharmacology of acute effort angina. Cardiovasc Drugs Ther 1989;3:257-70.
5. Kern MJ, Deligonul U, Labovitz A. Influence of drug therapy on the ischemic response to acute coronary occlusion in man: supply-side economics. Am Heart J 1989;118:361-80.
6. Thollon C, Cambarrat C, Vian J, Prost JF, Peglion JL, Vilaine JP. Electrophysiological effects of S-16257, a novel sino-atrial node modulator, on rabbit and guinea pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol 1994;112:37-42.
7. Simon L, Ghaleh B, Puybasset L, Giudicelli J, Berdeaux A. Coronary and hemodynamic effects of S-16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995;275:659-66.
8. Gardiner S, Kemp P, March J, Bennett T. Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S-16257, in conscious rats. Br J Pharmacol 1995;115:579-86.
9. Funck-Brentano C, Thomas G, Jacz-Aigrain E, Poirier JM, Simon T, Bereziat G. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. J Pharmacol Exp Ther 1992; 263:780-6.
10. Jamin P, Le Coz F, Funck-Brentano C, Poirier JM, Jaillon P. Relationships between acute and chronic beta-blocking effects of bisoprolol in healthy volunteers: a practical approach to predict intensity of beta-blockade. J Cardiovasc Pharmacol 1994;23:658-63.
11. Beal SL, Boeckman AJ, Sheiner LB. NONMEM user's guide, parts I-VI. San Francisco: Division of Clinical Pharmacology, University of California; 1992.
12. Danhof M, Mandema JW, Stijnen AM. Pharmacokinetic complexities of pharmacodynamic studies in vivo. In: Boxtel V, Holford M, Danhof M, editors. In vivo study of drug action. Amsterdam: Elsevier; 1992. p. 31-60.
13. Sheiner LB, Ludden TM. Population pharmacokinetics/ dynamics. Annu Rev Pharmacol Toxicol 1992;32:185-209.
14. Frishman WH, Pepine CJ, Weiss RJ, Baiker WM. Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina taking extended-release nifedipine: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. J Am Coll Cardiol 1995; 26:305-12.
15. Perez O, Gay P, Franqueza L. Effects of the two enantiomers, S-16257-2 and S-16260-2, of a new bradycardic agent on guinea-pig isolated cardiac preparations. Br J Pharmacol 1995;115:787-94.
16. Carré F, Denolle T, Le Coz F, Violet I, Lerebours G, Gandon JM. First intravenous phase I of S-16257, a new bradycardic agent: effects on the maximal exercise parameters [abstract]. Therapie 1995;50(suppl):377.
17. Boyd RA, Chin SK, Don-Pedro O, et al. The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. Clin Pharmacol Ther 1989;46:408-19.
18. Kaneko A, Tachibana M. Voltage-dependent membrane currents in solitary bipolar cells of the goldfish retina. J Physiol 1985;358:131-52.